- Park, John;
- Rugo, HS;
- Jo, A;
- Franco, SX;
- Stopeck, AT;
- Glencer, A;
- Lahiri, S;
- Arbushites, MC;
- Scott, J;
- Park, JW;
- Hudis, C
Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)-targeted agents has antitumor activity; these data indicate certain patients with HER
